Here, we test whether BCL2 overexpression predicts poor therapeutic response of HNSCC to cisplatin-based chemoradiotherapy and the effects of selective BCL2 inhibition on cisplatin-induced cell changes in vitro. This evidence concerns the gene BCL2 and head and neck squamous cell carcinoma.